Mutated Ephrin Receptor Genes in Non-Small Cell Lung Carcinoma and Their Occurrence with Driver Mutations-Targeted Resequencing Study on Formalin-Fixed, Paraffin-Embedded Tumor Material of 81 Patients

2013 ◽  
Vol 52 (12) ◽  
pp. 1141-1149 ◽  
Author(s):  
Satu Mäki-Nevala ◽  
Virinder Kaur Sarhadi ◽  
Katja Tuononen ◽  
Sonja Lagström ◽  
Pekka Ellonen ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Tumor Material ◽  
Formalin Fixed

scholarly journals Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine

2013 ◽  
Vol 137 (4) ◽  
pp. 481-491 ◽  
Author(s):  
Kirtee Raparia ◽  
Celina Villa ◽  
Malcolm M. DeCamp ◽  
Jyoti D. Patel ◽  
Minesh P. Mehta
Keyword(s):  
Lung Cancer ◽  
Lung Carcinoma ◽  
Molecular Mechanisms ◽  
Early Stage ◽  
Small Cell Lung Carcinoma ◽  
Locally Advanced ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

Context.—Lung carcinoma is the result of sequential accumulation of genetic and epigenetic changes. Lung adenocarcinoma is a heterogeneous disease with diverse somatic mutations, and several of them include the so-called driver mutations, which may serve as “druggable” therapeutic targets. Thus, development of personalized approaches for the treatment of non–small cell lung carcinoma (NSCLC) mandates that pathologists make a precise histologic classification inclusive of routine molecular analysis of such tumors. Objective.—To address the molecular mechanisms underlying NSCLC and how this knowledge reflects the multidisciplinary approach in the diagnosis and management of these patients. We will also summarize the current available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, and metastatic NSCLC. Data Sources.—Peer-reviewed published literature and personal experience. Conclusions.—There are multiple mechanisms involved in the pathogenesis of lung cancer, which operate in parallel and involve pathways of activation and inhibition of various cellular events. Further research is essential to characterize the histologic and mutational profiles of lung carcinomas, which will ultimately translate into improved and more personalized therapeutic management of patients with lung cancer.

scholarly journals Clinical Performance Evaluation of the Idylla™ Egfr Mutation Test on Formalin-Fixed Paraffin-Embedded Tissue of Non-Small Cell Lung Cancer

2020 ◽  
Author(s):  
Mercedes Delgado-Garcia ◽  
Birgit Weynand ◽  
Lourdes Gómez Izquierdo ◽  
María José Hernández Barrera ◽  
Ángela María Blanco Lobo ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Small Cell ◽  
Test Method ◽  
Small Cell Lung ◽  
Diagnostic Agreement ◽  
Cell Lung Carcinoma ◽  
Mutational Status ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Formalin Fixed

Abstract Background: detection of epidermal growth factor receptor (EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System.Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla).Results: the overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: the Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.

scholarly journals STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma

PLoS ONE ◽  
2012 ◽  
Vol 7 (2) ◽  
pp. e30820 ◽  
Author(s):  
Brendan D. Looyenga ◽  
Danielle Hutchings ◽  
Irene Cherni ◽  
Chris Kingsley ◽  
Glen J. Weiss ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Oncogenic Driver

Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis

2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Features ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document